RARE
Ultragenyx Pharmaceutical Inc.
$15.65
-1.88%
2026-10-23
About Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701, an adeno-associated AAV9 gene therapy which is in Phase 2 clinical trial for the treatment of Wilson liver disease. The company has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Regeneron; and Abeona. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Key Fundamentals
Forward P/E
21.43
EPS (TTM)
$-5.83
ROE
-608.5%
Revenue Growth (YoY)
28.1%
Profit Margin
-81.7%
Price/Book
-4.90
Beta
0.32
Market Cap
$1.43B
Avg Volume (10D)
6.8M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$28.50
60D Low
$12.73
Avg Volume
4.3M
Latest Close
$15.65
Get breakout alerts for RARE
Sign up for Breakout Scanner to receive daily notifications when RARE triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Ultragenyx Pharmaceutical Inc. (RARE) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors RARE daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. RARE operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.